COCOA, Fla., Aug. 23, 2011 /PRNewswire/ — GeNO LLC, (www.genollc.com) a privately held, advanced development-stage technology company, today announced that it has received a new federal grant to help fund the development of its NITROSYL(TM) (Nitric Oxide for Inhalation) System for the treatment of multiple chronic pulmonary diseases. Last year, the company also received a US Treasury grant to develop the system, based on its potential to fill the unmet medical need for an ultra-pure inhaled nitric oxide (NO) drug in this disease setting.
The Phase I SBIR grant will help establish a research partnership involving GeNO and Steward St. Elizabeth’s Medical Center, Boston, MA, to study the physiological performance and biocompatibility of the GeNO liquid source (N2O4) delivery system for the delivery of inhaled NO compared with the GeNO gas cartridge system (which converts NO2) in a porcine model of acute respiratory failure.
Read the entire article at:
or go to www.ipftoday.com for more news.